Hims & Hers Surges 7%+ on Eli Lilly Partnership for GLP-1 Sales

Hims & Hers Health (HIMS) shares are up over 7% premarket after striking a deal with Eli Lilly (LLY) to directly sell obesity drugs Zepbound and Foundayo on its platform [1].

Key points:

• HIMS now offers direct access to both leading GLP-1 drugmakers, Lilly and Novo Nordisk.
• The partnership removes friction for consumers, as Lilly's drugs were previously only available via LillyDirect after leaving the HIMS site.
• HIMS has agreed not to sell compounded versions of Lilly's obesity medications.
• Self-pay pricing for Lilly's drugs on HIMS matches LillyDirect, starting at $149/month for Foundayo and $299/month for Zepbound [1].